{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T18:43:02Z","timestamp":1758393782905},"reference-count":18,"publisher":"LLC Obyedinennaya Redaktsiya","issue":"6","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>The purpose of our study is to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1R agonists) on early markers of kidney damage in patients with type 1 diabetes mellitus (DM). Materials and methods. The study included 27 patients with type 1 diabetes with normo- (n=16) and microalbuminuria (n=11) on intensive insulin injection regimen with insulin analogs. Patients were divided into two groups: 15 patients continued insulin therapy throughout the follow-up period, 12 patients were given 1.2 mg GLP-1R agonist (Liraglutide) once a day in addition to the insulin therapy for 6 months. HbA1c, lipid profile, classic markers of kidney damage (albuminuria, creatinine, glomerular filtration rate); plazma (neutrophilic gelatinase-associated lipoxalin - NGAL, molecule renal damage of type 1 - KIM-1, cystatin C, osteopontin) and urinary kidney biomarkers (nephrin, podocyne, uromodulin, NGAL, KIM-1, collagen type IV, cystatin C) were evaluated prior and in dynamics at 6 months. Kidney biomarkers levels were assessed by the enzyme-linked immunosorbent assay (ELISA). Results. We observed a significant decrease in the urinary excretion of type IV collagen, cystatin C, increased uromodulin excretion and decrease in the plasma levels of osteopontin, NGAL and cystatin C in the group of combined insulin and GLP-1R agonist therapy. Conclusions. Changes in the level of sensitive kidney biomarkers indicate a possible renoprotective effect of GLP-1R agonist therapy in patients with type 1 diabetes at an early stages of kidney damage.<\/jats:p>","DOI":"10.26442\/terarkh201890659-64","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T19:47:08Z","timestamp":1540237628000},"page":"59-64","source":"Crossref","is-referenced-by-count":2,"title":["Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus"],"prefix":"10.26442","volume":"90","author":[{"given":"O K","family":"Vikulova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z T","family":"Zuraeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O V","family":"Michaleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L V","family":"Nikankina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Sh","family":"Shamkhalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M V","family":"Shestakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I I","family":"Dedov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14341\/DM8664"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(14)70106-X"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000437542.77175.a"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14341\/2072-0351-5517"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v5.i6.763"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000339028"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2012.03.002"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0172-3"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1824"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000337929"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2011.01.010"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-017-0423-9"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2017"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-017-2015-x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0065"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32775\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T17:53:34Z","timestamp":1593453214000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/32775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,15]]}},"URL":"https:\/\/doi.org\/10.26442\/terarkh201890659-64","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,15]]}}}